NCT00625859View on ClinicalTrials.gov

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 16, 2008

Primary Completion Date

April 10, 2008

Study Completion Date

April 10, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GSK189075

GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

DRUG

Bupropion

Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.

DRUG

Placebo

Placebo tablets will be given to subjects.

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY